Hjem › Leverkreft (hepatocellulært karcinom) › Pennsylvania › Philadelphia
Kliniske studier for Leverkreft (hepatocellulært karcinom) i Philadelphia, PA
16 studier for Leverkreft (hepatocellulært karcinom) søker deltakere på steder i og rundt Philadelphia (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekruttererFase 1
- Exelixis Clinical Site #98, Philadelphia
National Liver Cancer Screening Trial
RekruttererFase 4
- University of Pennsylvania, Philadelphia
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
RekruttererFase 3
- Research Site, Philadelphia
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RekruttererFase 1/2
- Children's Hospital of Philadelphia, Philadelphia
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RekruttererFase 1/2
- University of Pennsylvania, Perelman School of Medicine, Philadelphia
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
RekruttererFase 3
- Christiana Care Health System-Concord Health Center, Chadds Ford · 23 mi unna
- Christiana Care Health System-Wilmington Hospital, Wilmington · 25 mi unna
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RekruttererFase 2
- Thomas Jefferson University, Philadelphia
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
Rekrutterer
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia
Y-90 Treatment Response Using Transarterial Radioembolization
RekruttererFase 2
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
RekruttererFase 1/2
- University of Pennsylvania, Philadelphia
Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
RekruttererFase 1/2
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
RekruttererFase 2
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
SBRT With Atezo/Bev for HCC
RekruttererFase 1
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients
RekruttererObservasjonsstudie
- Thomas Jefferson Hospital, Philadelphia
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
RekruttererFase 4
- Albert Einstein Healthcare Network, Philadelphia
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Philadelphia
Leverkreft (hepatocellulært karcinom)-studier i andre byer
- Houston, TX31 studier
- New York City, NY24 studier
- Dallas, TX19 studier
- Los Angeles, CA19 studier
- Boston, MA18 studier
- Cleveland, OH18 studier
- Chicago, IL16 studier
- Pittsburgh, PA15 studier
- San Francisco, CA14 studier
- Orange, CA14 studier
- Jacksonville, FL14 studier
- San Antonio, TX13 studier
Andre studier i Philadelphia
- Kreft (alle typer)59 studier
- Brystkreft56 studier
- Ikke-småcellet lungekreft51 studier
- Metastatisk kreft46 studier
- Prostatakreft44 studier
- Kolorektal kreft44 studier
- Eggstokkreft44 studier
- Lungekreft36 studier
- Akut myelogen leukemi34 studier
- Hjertesvikt31 studier
- Endometriekreft28 studier
- Depresjon26 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.